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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 210, Revision 1 
(FGE.210Rev1): Consideration of genotoxic potential for α,β-unsaturated 
alicyclic ketones and precursors from chemical subgroup 2.4 of FGE.19
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of 13 flavouring substances in Flavouring Group 
Evaluation 210 (FGE.210) and one additional substance [FL-no: 07.225] in this revision 1 (FGE.210Rev1). In 
the first version of FGE.210 the Panel concluded that a genotoxic potential could not be ruled out for any of the 
13 substances based on data available at that time. The Flavouring Industry has now submitted additional 
genotoxicity data. The Panel has evaluated these data and concluded that the concern for genotoxic potential is 
ruled out for eight of the substances [FL-no: 02.105, 07.007, 07.009, 07.011, 07.036,  07.088, 07.091 and 
07.170], while for allyl alpha-ionone [FL-no: 07.061] and for alpha-damascone [FL-no: 07.134] and four 
structurally related substances [FL-no: 07.130, 07.225, 07.226 and 07.231] the concern still remains with respect 
to genotoxicity. 
© European Food Safety Authority, 2014 
 
KEY WORDS 
α,β-unsaturated ketones, flavouring substances, safety evaluation, FGE.210, subgroup 2.4, FGE.19 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2013-00268 to EFSA-Q-2013-00276 and EFSA-Q-
2013-00555 to EFSA-Q-2013-00559, adopted on 30 January 2014. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, 
Alessandro Di Domenico, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter 
Jany, Martine Kolf-Clauw, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de Fatima Tavares 
Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu  
3  The Panel wishes to thank the members of the Genotoxicity Working Group on Flavourings : Mona-Lise Binderup, 
Claudia Bolognesi, Angelo Carere, Riccardo Crebelli, Rainer Gürtler, Natália Kovalkovičová, Daniel Marzin and Pasquale 
Mosesso for the preparatory work on this scientific opinion and, the hearing experts: Vibe Beltoft, Pia Lund and Karin 
Nørby and, EFSA staff: Annamaria Rossi, Maria Carfi, Silvia Moretti and Kim Rygaard Nielsen for the support provided 
to this scientific opinion. 
 
Flavouring Group Evaluation 210, Revision 1 
 
EFSA Journal 2014;12(2):3587 2 
SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF) was asked to deliver a scientific opinion on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate flavouring substances using the 
Procedure as referred to in the Commission Regulation (EC) No 1565/2000.  
The Flavouring Group Evaluation 210 (FGE.210) concerned 13 substances, belonging to subgroup 2.4 
of FGE.19. Twelve of these substances are α,β-unsaturated alicyclic ketones (alpha-ionone [FL-no: 
07.007], methyl-alpha-ionone [FL-no: 07.009], 4-(2,5,6,6-tetramethyl-2-cyclohexenyl)-3-buten-2-one 
[FL-no: 07.011], alpha-isomethyl ionone [FL-no: 07.036], allyl alpha-ionone [FL-no: 07.061], methyl-
delta-ionone [FL-no: 07.088], gamma-ionone [FL-no: 07.091], delta-damascone [FL-no: 07.130], 
alpha-damascone [FL-no: 07.134], beta-ionone epoxide [FL-no: 07.170], tr-1-(2,6,6-trimethyl-2-
cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.226] and alpha-damascenone [FL-no: 07.231]) and one 
substance (4-(2,6,6-trimethyl-2-cyclohexenyl)but-3-en-2-ol [FL-no: 02.105]) is a precursor for such 
ketone. One of the substances  (allyl alpha-ionone [FL-no: 07.061]) has a terminal double bond and 
one (beta-ionone epoxide [FL-no: 07.170]) is an epoxide . 
The genotoxicity concern with respect to the 13 α,β-unsaturated alicyclic ketones and precursors in 
FGE.210 could not be ruled out based on the genotoxicity data and (Quantitative) Structure-Activity 
Relationship ((Q)SAR) predictions available.  
The present revision of FGE.210 (FGE.210Revision1) has been prepared due to additional 
genotoxicity data submitted by the Industry on representative substances (alpha-ionone [FL-no: 
07.007], allyl alpha-ionone [FL-no: 07.061], beta-ionone epoxide [FL-no: 07.170] and alpha-
damascone [FL-no: 07.134]). Also an additional substance has been included, cis-1-(2,6,6-trimethyl-2-
cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.225]. 
The Panel has evaluated these data and concluded that the concern for genotoxic potential is ruled out 
for eight of the substances [FL-no: 02.105, 07.007, 07.009, 07.011, 07.036,  07.088, 07.091 and 
07.170]. These eight substances can accordingly be evaluated using the Procedure. For allyl alpha-
ionone [FL-no: 07.061] and for alpha-damascone [FL-no: 07.134] and the four structurally related 
substances [FL-no: 07.130, 07.225, 07.226 and 07.231], the new submitted data could not rule out the 
Panel concern with respect to genotoxicity and additional data are requested.   
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavouring is regulated under Regulation (EC) No 1334/2008
4
 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union List of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5
. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6
. 
EFSA has evaluated 13 flavouring substances, which correspond to subgroup 2.4 of FGE.19, in its 
evaluation of the flavouring group 210 (FGE.210). The opinion was adopted on 29 January 2009. 
EFSA concluded that a genotoxic potential of these α,β-unsaturated alicyclic ketones and precursors in 
the present FGE.210 could not be ruled out. 
Information on three representative materials alpha-ionone [FL-no: 07.007], allyl alpha-ionone [FL-
no: 07.061] and beta-ionone epoxide [FL-no: 07.170] has now been submitted by the European 
Flavour Association. This information is intended to cover the re-evaluation of the above mentioned 
substances and of six substances from FGE.19 subgroup 2.4 [FL-no: 02.105, 07.009, 07.011, 07.036, 
07.088 and 07.091].  
 4-(2,6,6-Trimethyl-2-cyclohexenyl)but-3-en-2-ol [FL-no: 02.105] 
 Methyl-alpha-ionone [FL-no: 07.009] 
 4-(2,5,6,6-Tetramethyl-2-cyclohexenyl)-3-buten-2-one [FL-no: 07.011] 
 alpha-Isomethyl ionone [FL-no: 07.036] 
 Methyl-delta-ionone [FL-no: 07.088] 
 gamma-Ionone [FL-no: 07.091] 
Additionally, new information on one further representative material alpha-damascone [FL-no: 
07.134] and on one other substance, delta-damascone [FL-no: 07.130], has now been submitted by the 
European Flavour Association. This information is intended to cover also the re-evaluation of the 
following flavouring substances from FGE.19 subgroup 2.4 
 cis-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.225] 
 tr-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.226] 
 alpha-damascenone [FL-no: 07.231] 
                                                     
4
  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5
  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012,  
p. 1-161. 
6
  Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following flavouring substances in the present FGE: 4-(2,6,6-trimethyl-2-
cyclohexenyl)but-3-en-2-ol [FL-no: 02.105], alpha-ionone [FL-no: 07.007], methyl-alpha-ionone [FL-
no: 07.009], 4-(2,5,6,6-tetramethyl-2-cyclohexenyl)-3-buten-2-one [FL-no: 07.011], alpha-isomethyl 
ionone [FL-no: 07.036], allyl alpha-ionone [FL-no: 07.061], methyl-delta-ionone [FL-no: 07.088], 
gamma-ionone [FL-no: 07.091], delta-damascone [FL-no: 07.130], alpha-damascone [FL-no: 07.134], 
beta-ionone epoxide [FL-no: 07.170], cis-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)but-2-en-1-one [FL-
no:07.225], tr-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)but-2-en-1-one [FL-no:07.226] and alpha-
damascenone [FL-no: 07.231] in accordance with Commission Regulation (EC) No 1565/2000. 
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HISTORY OF THE EVALUATION OF FGE.19 SUBSTANCES 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008a). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a). The Panel noted that there were limited genotoxicity data on these flavouring substances but 
that positive genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these alpha, beta- unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and 
decided not to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008a) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established: 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225). 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a 
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the 
Procedure. For all or some of the substances in the remaining FGEs, FGE.201. 203, 210, 212, 213, 
216, 217 and 220 the genotoxic potential could not be ruled out. 
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA worked out a list of representative 
substances for each subgroup (EFSA, 2008c). Likewise an EFSA genotoxicity expert group has 
worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b). 
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup. 
The Flavouring industry has now submitted additional data and the present FGE concerns the 
evaluation of these data requested on genotoxicity. 
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ASSESSMENT 
1. History of the Evaluation of the Substances Belonging to FGE.210 
In FGE.210 EFSA considered 13 flavouring substances corresponding to subgroup 2.4 of FGE.19. 
Twelve of these substances are α,β-unsaturated alicyclic ketones [FL-no: 07.007, 07.009, 07.011, 
07.036, 07.061, 07.088, 07.091, 07.130, 07.134, 07.170, 07.226 and 07.231] and one (4-(2,6,6-
trimethyl-2-cyclohexenyl)but-3-en-2-ol [FL-no: 02.105]) is a precursor for such ketone. One of the 
substances (allyl alpha-ionone [FL-no: 07.061]) has a terminal double bond and one (beta-ionone 
epoxide [FL-no: 07.170]) is an epoxide. 
The genotoxicity concern with respect to the 13 α,β-unsaturated alicyclic ketones and precursors could 
not be ruled out based on the genotoxicity data and the (quantitative) structure-activity relationship 
((Q)SAR) predictions available. The Panel therefore concluded that additional data on genotoxicity on 
substances representative for this subgroup should be provided according to the Genotoxicity Test 
Strategy for Substances Belonging to Subgroups of FGE.19 (EFSA, 2008b). 
FGE Adopted by 
EFSA 
Link No. of 
Substances 
FGE.210 29 January 2009 http://www.efsa.europa.eu/en/efsajournal/pub/1030.htm 13 
FGE.210Rev1 30 January 2014  14 
 
The present revision of FGE.210 (FGE.210Rev1) concerns the evaluation of additional data submitted 
by Industry for the representative substances alpha-ionone [FL-no: 07.007], allyl alpha-ionone [FL-no: 
07.061], beta-ionone epoxide [FL-no: 07.170] (IOFI, 2013a) and alpha-damascone [FL-no: 07.134] 
(IOFI, 2013b) (Table 1). Data on beta-damascone [FL-no: 07.083] (belonging to subgroup 2.7b of 
FGE.19) have also been provided as representative of the damascone-type substances. However, the 
Panel disagrees with this structural related similarity and beta-damascone [FL-no: 07.083] will be 
considered a representative substance only for subgroup 2.7b of FGE.19 (FGE.213) as indicated in the 
“List of alpha- and beta-unsaturated aldehydes and ketone representative of FGE.19 substances for 
genotoxicity” (EFSA, 2008c). Furthermore, data on genotoxicity of delta-damascone [FL-no: 07.130] 
have been submitted. 
Table 1:  Representative substances for Subgroup 2.4 of FGE.19 (EFSA, 2008c) 
Subgroup FL-no Register name for representatives Structural formula 
Ionone-related 07.007 alpha-Ionone O
 
07.061 Allyl alpha-ionone 
O
 
07.170 beta-Ionone epoxide 
O
O
 
Damascone-
related 
07.134 alpha-Damascone O
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Since the previous version of FGE.210 one additional substance has been included in subgroup 2.4, 
cis-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.225]. 
Section 2 and 3 report the same information that was presented in the previous version of FGE.210. 
Section 4 report the new submitted data. 
 
2. Presentation of the Substances in Flavouring Group Evaluation 210Rev1 
2.1. Description 
The Flavouring Group Evaluation 210 (FGE.210) concerns 14 substances, corresponding to subgroup 
2.4 of FGE.19 (see Table 2). Thirteen of these substances are α,β-unsaturated alicyclic ketones [FL-
no: 07.007, 07.009, 07.011, 07.036, 07.061, 07.088, 07.091, 07.130, 07.134, 07.170, 07.225 (not 
present in FGE.210), 07.226 and 07.231] and one is a precursor for such ketone [FL-no: 02.105]. One 
of the substances has a terminal double bond [FL-no: 07.061] and one is an epoxide [FL-no: 07.170].  
Eleven of the substances in the present FGE have previously been evaluated by the JECFA, a 
summary of their current evaluation status by the JECFA is given in Table 3 (JECFA, 1999; JECFA, 
2006). 
As the α,β-unsaturated ketone structure is a structural alert for genotoxicity (EFSA, 2008a), the 
available data on genotoxic or carcinogenic activity for the 13 α,β-unsaturated ketones [FL-no: 07.007, 
07.009, 07.011, 07.036, 07.061, 07.088, 07.091, 07.130, 07.134, 07.170, 07.225, 07.226 and 07.231] 
and a precursor for such ketone [FL-no: 02.105], will be considered in this FGE. 
3. Data evaluated by the Panel in FGE.2107 
3.1. (Q)SAR Predictions 
The Panel has also taken into consideration the outcome of the predictions from five selected 
(Quantitative) Structure-Activity Relationship ((Q)SAR) models (Benigni & Netzeva, 2007a; Gry et 
al., 2007; Nikolov et al., 2007) on twelve ketones [FL-no: 07.007, 07.009, 07.011, 07.036, 07.061, 
07.088, 07.091, 07.130, 07.134, 07.170, 07.226 and 07.231] in the original version of FGE.210.  
In Table 4 the outcomes of the (Q)SAR predictions for possible genotoxic activity in five in vitro 
(Q)SAR models (ISS-Local Model-Ames test, DTU-NFI MultiCASE-Ames test, Chromosomal 
aberration test in Chinese hamster ovary (CHO) cells, Chromosomal aberration test in Chinese 
hamster lung (CHL) cells, and Mouse lymphoma test) are presented. 
For all of the substances the (Q)SAR models predict negative results in tests for gene mutations, with 
the restriction that about half of the substance predictions are out of domain for the Mouse lymphoma 
assay. It is noted that predictions for chromosomal aberrations (CA) are diverging in the sense that for 
CAs in Chinese hamster ovary cells the predictions are invariably negative (three are out of domain), 
while for the same endpoint in another but very similar cell type (Chinese hamster lung cells) only for 
one substance a negative response was predicted. For most of the remaining substances the predictions 
in the CA (CHL) test were equivocal and for four substances the predictions were out of domain 
(Table 4). 
                                                     
7
  The data presented in Section 3 is cited from the first version of FGE.210. These data are the basis for the conclusions in 
FGE.210 requesting additional genotoxicity data. 
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3.2. Genotoxicity Studies 
In subgroup 2.4 there are two in vitro studies on alpha-ionone [FL-no: 07.007], one in vitro study on 
methyl-alpha-ionone [FL-no: 07.009] and one in vitro study on methyl-delta-ionone [FL-no: 07.088]. 
Only one in vivo study for methyl-alpha-ionone [FL-no: 07.009] is available for this subgroup. 
Study validation and results are presented in Tables 5 and 6. 
The available in vitro bacterial gene mutation studies with limited validities do not indicate a concern 
for the tested substances from this group. One of the in vitro tests (Rec assay) is in a system which has 
limited predictive validity for genotoxicity. An in vivo test with limited validity produced a negative 
result for gene mutations in Drosophila melanogaster. A limited in vitro test for structural 
chromosomal damage produced a positive response with alpha-ionone, but a limited in vivo 
mammalian test for the same endpoint with alpha-ionone gave a negative outcome. 
3.3. Carcinogenicity Studies 
No carcinogenicity studies are available for the substances in subgroup 2.4. 
3.4. Conclusion on Genotoxicity and Carcinogenicity 
The data ((Q)SAR and testing data) are not sufficient to rule out a concern for genotoxicity for these 
substances. 
3.5. Conclusions 
The Panel concluded that a genotoxic potential of the 13 α,β-unsaturated alicyclic ketones and 
precursors in the present FGE.210 [FL-no: 02.105, 07.007, 07.009, 07.011, 07.036, 07.061, 07.088, 
07.091, 07.130, 07.134, 07.170, 07.226 and 07.231] could not be ruled out based on the data available. 
Accordingly these 13 substances cannot be evaluated through the Procedure, presently. Additional 
data on genotoxicity on substances representative for this subgroup should be provided according to 
the Genotoxicity Test Strategy for substances belonging to Subgroups of FGE.19 (EFSA, 2008b). 
4. Additional Genotoxicity Data Submitted for FGE.19 Subgroup 2.4 (FGE.210) 
4.1. Presentation of the Additional Data 
The present revision of FGE.210 (FGE.210Rev1), concerns the evaluation of additional data submitted 
by Industry for the representative substances alpha-ionone [FL-no: 07.007], allyl alpha-ionone [FL-no: 
07.061], beta-ionone epoxide [FL-no: 07.170] and alpha-damascone [FL-no: 07.134] for subgroup 2.4 
(EFSA, 2008a). Furthermore, data on genotoxicity of delta-damascone [FL-no: 07.130] have been 
submitted. 
In response to the EFSA request in FGE.210 for additional genotoxicity data for subgroup 2.4, the 
Flavour Industry (IOFI, 2013a; 2013b) has submitted genotoxicity data on: 
Substance  Bacterial Mutation In vitro Micronucleus In vivo Micronucleus 
alpha-Ionone [FL-no: 07.007] (Bowen, 2011) (Lloyd, 2013b) 
(Krsmanovic and 
Huston, 2006) 
Allyl alpha-ionone [FL-no: 07.061] (Ballantyne, 2011) (Lloyd, 2013a)  
delta-Damascone [FL-no: 07.130] (Shinya, 2006)   
alpha-Damascone [FL-no: 07.134] (Haddouk, 2001) 
(Lloyd, 2012; Lloyd, 
2013c; Whitwell, 2012) 
 
beta-Ionone epoxide [FL-no: 07.170] 
(Jones and Wilson, 
1988; Kringstad, 2005) 
(Flanders, 2006)  
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4.2. In vitro data 
4.2.1. Bacterial Reverse Mutation Assay 
alpha-Ionone [FL-no: 07.007] 
An Ames assay was conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537, 
and TA102 to assess the mutagenicity of alpha-ionone, both in the absence and in the presence of 
metabolic activation by S9-mix (from livers of rats induced with Aroclor 1254), in three separate 
experiments (Bowen, 2011). This study was performed following GLP recommendations and 
according to OECD Guideline 471 (OECD, 1997a). An initial experiment was carried out both in the 
absence and presence of S9-mix activation in all five strains, using  0.3, 1.6, 8, 40, 200, 1000 and 5000 
μg of alpha-ionone/plate, plus negative (solvent) and positive controls. Evidence of toxicity was 
observed at 1000 and/or 5000 μg/plate across all strains in the absence and presence of S9-mix with 
the exception of TA100 in which no clear evidence of toxicity, in presence of S9-mix, was observed at 
5000 µg/plate (Table 7).  
In a second experiment, the concentrations were changed lowering to 2500 µg/plate for all strains and 
conditions with the exception of TA98 in presence of S9-mix and for TA100 in presence and absence 
of S9-mix. In this second experiment the concentration intervals were narrowed, covering the ranges 
156.3 - 5000 µg/plate or 78.1 - 2500 µg/plate in order to better detect possible concentration-
dependent mutation. In addition, a pre-incubation step with S9-mix activation treatment was added to 
increase the chance of detecting a positive response. In this experiment, evidence of toxicity ranging 
from a diminution of the background bacterial lawn and/or a reduction in revertant numbers to a 
complete killing of the test bacteria was observed at 1250 μg/plate and above for strain TA98 in the 
presence of S9-mix, at 625 μg/plate in strains TA98 in the absence of S9-mix and TA100 with and 
without S9-mix. Toxicity was observed at 312.5 μg/plate and above in all remaining strains.  
The third experiment was conducted using strains TA1535 and TA102 in the absence and presence of 
S9-mix activation and strain TA1537 in the presence of S9-mix activation. In the treatment with S9-
mix a pre-incubation step was included. The maximum test concentration was 2500 μg/plate for 
TA1535 while it was further reduced for TA102 (with or without S9-mix) and for TA1537 to 1250 
μg/plate. In addition, more narrow concentration intervals were used, covering either 39.1 to 2500 
μg/plate or 19.5 to 1250 μg/plate. Evidence of toxicity was observed at the highest three or four 
concentrations across all strains in the absence or presence of S9-mix. 
In all three experiments, no statistically significant increases in revertant numbers were observed at 
any concentration, in any of the strains, either in the presence or absence of S9-mix activation. 
It was concluded that alpha-ionone did not induce mutations in five strains of S. typhimurium, when 
tested under the conditions of this study.  
Allyl alpha-ionone [FL-no: 07.061] 
An Ames assay was conducted in S. typhimurium strain TA102 to assess the mutagenicity of allyl 
alpha-ionone, both in the absence and in the presence of metabolic activation by S9-mix (from livers 
of rats induced with Aroclor 1254), in two separate experiments (Ballantyne, 2011). The study was 
performed following GLP principles and according to the OECD Guideline 471 (OECD, 1997a), 
except that only TA102 was used (Table 7). An initial experiment was carried out both in the absence 
and presence of S9-mix activation in the TA102 strain, using 1.6, 8, 40, 200, 1000 and 5000 μg of allyl 
alpha-ionone/plate plus vehicle and positive controls. In the second experiment, the highest 
concentration was retained but more narrow concentration intervals were used, starting at 51.2 
μg/plate (51.2, 128, 320, 800, 2000 and 5000 μg/plate). The standard plate incorporation assay was 
used in the first experiment and a pre-incubation step with S9-mix activation treatment was added in 
Flavouring Group Evaluation 210, Revision 1 
 
EFSA Journal 2014;12(2):3587 11 
the second experiment to increase the chance of detecting a positive response. No evidence of toxicity 
was observed under any of the conditions tested. 
In both experiments, no statistically significant increases in revertant numbers were observed at any 
concentration in strain TA102, either in the presence or absence of S9-mix activation. 
It was concluded that allyl alpha-ionone did not induce mutation in the histidine-requiring S. 
typhimurium strain TA102 when tested under the conditions of this study. The authors justified to test 
only TA102 strain because this study was intended to be complementary to a previous study from 
(Wild et al., 1983) where data on the other strains were provided.  
delta-Damascone [FL-no: 07.130] 
A modified Ames assay using the pre-incubation method was conducted in S. typhimurium strains 
TA98, TA100, TA1535, and TA1537 and Escherichia coli WP2uvrA to assess the mutagenicity of 
delta-damascone (purity: 93.8 %), both in the absence and in the presence of metabolic activation by 
S9-mix (from livers of rats induced with Aroclor 1254), in three separate experiments (Shinya, 2006). 
The assay was performed according to OECD Guideline 471 (OECD, 1997a) and according to GLP 
principles (Table 7).  
An initial experiment was carried out both in the absence and presence of S-9 mix activation in all five 
strains at 4.9, 19.5, 78.1, 313, 1250 and 5000 μg of delta-damascone/plate), plus negative (solvent) and 
positive controls. In the absence of S9-mix, toxicity (decrease of bacterial growth and/or of revertants) 
was reported at 78.1 μg/plate and above and in the presence of S9-mix, toxicity was reported at 313 
μg/plate and above. In the second experiment with tighter ranges of concentrations to reflect the 
toxicity observed in the previous experiment, delta-damascone was incubated with all five tester 
strains in the absence of S9-mix (2.4, 4.9, 9.8, 19.5, 39.1 or 78.1 μg of delta-damascone/plate) and in 
the presence of S9-mix (9.8, 19.5, 39.1, 78.1, 156 and 313 μg of delta-damascone/plate). Toxicity was 
observed in the absence of S-9 mix at top concentration and in the presence of S9-mix at 156 μg/plate 
and above. In the third experiment, the same conditions as described for the second experiment were 
used. In all three experiments there were no significant increases in the number of revertants in the 
absence or presence of S9-mix. It was concluded that delta-damascone did not induce mutations in 
four strains of S. typhimurium or E. coli WP2uvrA under the conditions employed (Shinya, 2006). 
alpha-Damascone [FL-no: 07.134] 
Ames assays were conducted in S. typhimurium strains TA1535, TA1537, TA98 and TA100 and 
Escherichia coli WP2uvrA to assess the mutagenicity of alpha-damascone (purity: 96.9 %), both in the 
absence and in the presence of metabolic activation by S9-mix (from livers of rats  induced with 
Aroclor 1254), in two separate experiments (Haddouk, 2001). The assay was performed according to 
OECD Guideline 471 (OECD, 1997a) and according to GLP principles (Table 7). 
An initial experiment to assess toxicity was carried out both in the absence and presence of S9-mix 
activation in the tester strains, using 10, 100, 500, 1000, 2500 and 5000 μg of alpha-damascone/plate 
in strains TA98, TA100 and WP2 uvrA, plus vehicle and positive controls. Concentration levels 
greater than or equal to 2500 μg/plate showed evidence of an emulsion on the plates. In TA98, slight 
to marked toxicity was observed at concentrations greater than or equal to 100 μg/plate or 500 μg/plate 
in the absence and presence of S9-mix, respectively. In TA100, toxicity was observed at 
concentrations greater than or equal to 500 μg/plate in the absence and presence of S9-mix. In E. coli 
WP2 uvrA slight toxicity was observed at 2500 μg/plate and above without S9-mix but not with S9-
mix. Based on the preliminary toxicity test, a standard Ames test using the plate incorporation method 
was conducted using 31.2, 62.5, 125, 250 and 500 μg of alpha-damascone/plate for strains TA1535 
and TA100 and 7.8, 15.6, 31.2, 62.5 and 125 μg of alpha-damascone/plate for strains TA1537 and 
TA98 in the absence and presence of S9-mix. Additionally alpha-damascone (312.5, 625, 1250, 2500 
and 5000 μg/plate) was tested in E. coli WP2 uvrA for reverse mutation in the absence and presence of 
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S9-mix. In the second experiment, alpha-damascone was tested in all S. typhimurium tester strains in 
the absence of S9-mix at the following concentrations: 15.6, 31.2, 62.5, 125 and 250 μg/plate. In the 
second experiment, the tests run in the presence of S9-mix were performed with the pre-incubation 
(modified Ames) method at concentrations of 31.2, 62.5, 125, 250 and 500 μg of alpha-
damascone/plate for strains TA1535 and TA100 and at concentrations of 15.6, 31.2, 62.5, 125 and 250 
μg of alpha-damascone/plate for strains TA1537 and TA98. Additionally alpha-damascone (312.5, 
625, 1250, 2500 and 5000 μg/plate) was tested in E. coli WP2 uvrA for reverse mutation in the 
absence of S9-mix (with the plate incorporation method) and in the presence of S9-mix (with the pre-
incubation method). Slight evidence of toxicity was observed under the conditions tested through 
thinning of the background bacterial lawn and/or a decrease in revertant count in Salmonella strains. In 
the E. coli strain, a slight toxicity was observed only at 5000 μg/plate in the absence of S9-mix. 
In both experiments, no statistically significant increases in revertant numbers were observed at any 
concentration in any of the strains, either in the presence or absence of S9-mix activation. 
It was concluded that alpha-damascone did not show mutagenic activity towards S. typhimurium or E. 
coli in the bacterial reverse mutation test (Haddouk, 2001). The Panel agreed with the conclusion of 
the author.  
beta-Ionone epoxide [FL-no: 07.170] 
beta-Ionone epoxide was tested for mutagenicity in an Ames test including four strains of S. 
typhimurium (TA98, TA100, TA1535 and TA1537) at five concentrations (5, 15, 50, 150, 500 
μg/plate) in the absence and in the presence of metabolic activation (S9-mix at two different 
concentrations, 3 and 10 %) (Jones and Wilson, 1988). The study was performed under GLP and 
mainly compliant with OECD Guideline 471 (OECD, 1997a), except that only four strains were used 
(Table 7). Two independent experiments were performed and the top concentration was selected at 
500 μg/plate based on toxicity in a prior range-finding test. At the concentration tested no significant 
toxicity was observed and no substantial increases in mutation were observed in all strains tested and 
in presence or absence of S9. 
A more recently reported Ames study on beta-ionone-epoxide included four strains of S. typhimurium 
(TA97a, TA98, TA100, TA1535) plus one strain of E. coli (WP2-uvrA-) (Kringstad, 2005). Following 
a range-finding assay, beta-ionone was tested in three replicates at 501, 1582 and 5000 μg/plate in the 
absence of S9-mix metabolic activation and at 158, 501 and 1582 μg/plate in the presence of metabolic 
activation, in a single experiment using the plate incorporation method. The top concentration (5000 
μg/plate) induced significant toxicity in strain TA97a in the absence of S9-mix and also reduced the 
background lawn in strain TA100 in the presence and absence of S9-mix and therefore the study 
complies with current recommendations for the choice of concentration. There was no evidence of 
mutagenicity. Since there are some deviations from the OECD Guideline 471 (OECD, 1997a) (only 
three concentrations of chemical were tested, in some cases only two concentrations could be analysed 
due to an excessive level of cytotoxicity and only a single experiment was performed) the test is 
considered of limited validity.  
4.2.2. Mouse lymphoma thymidine kinase gene mutation assay 
beta-Ionone epoxide [FL-no: 07.170] 
An assay for induction of tk mutations in mouse lymphoma cells (L5178Y T/K +/- 3.7.2c) was 
conducted on beta-ionone-epoxide (Flanders, 2006). It included 4 hours treatment in the absence and 
presence of S9-mix and a 24 hours treatment in the absence of S9-mix. The concentrations were 
selected based on a preliminary toxicity test. The test groups included single replicates at 8 
concentrations ranging from 200 to 900 μg/ml in the 4 hours treatment arm and from 4.1 to 520 μg/ml 
in the 24 hours treatment arm. The maximum concentration was limited by toxicity. The substance did 
not induce  biologically or statistically significant increases in mutant frequency and therefore it was 
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considered non-mutagenic in this assay. The study is compliant with OECD Guideline 476 (OECD, 
1997c)  (Table 7). 
4.2.3. Micronucleus Assays 
alpha-Ionone [FL-no: 07.007] 
alpha-Ionone was evaluated in an in vitro micronucleus assay in human peripheral blood lymphocytes 
for its ability to induce chromosomal damage or aneuploidy in the presence and absence of rat S9-mix 
fraction (Table 7). Information about the method used to induce lymphocyte cell division and the 
duration of the induction before the treatment was not provided. Cells were treated for 24 hours with 
14 concentrations in a range from 15 to 120 µg/ml of alpha-ionone in absence of S9-mix. In presence 
of S9-mix, cells were exposed for 3 hours followed by 21 hours recovery with 15 concentrations in a 
range from 30 to 200 µg/ml. Based on the toxicity induced by alpha-ionone, three concentrations were 
selected for micronuclei assessment. In absence of S9-mix, cells were treated with 40, 50 and 65 
µg/mL, while in presence of S9-mix the concentrations selected were 160, 170 and 180 µg/ml. The 
highest concentrations induced 51 % and 56 % reduction of replicative index (RI) in absence and 
presence of S9-mix, respectively. Micronuclei assessment was performed in a single experiment with 
duplicates and a total of 1000 binucleate cells per replicate were scored. No assay with 3-hour 
treatment + 21-hour recovery in absence of S9-mix was performed as recommended by OECD 
Guideline 487 (OECD, 2010).  Treatment of cells with alpha-ionone for 3 hours with a 21 hours 
recovery period in the presence of S9-mix or for 24 hours with no recovery period in the absence of 
S9-mix showed no increase in the frequency of MNBN cells at any concentration when compared to 
both concurrent and historical controls. It was concluded that alpha-ionone did not induce micronuclei 
at up to the limit of toxicity when assayed in cultured human peripheral lymphocytes under the 
described exposure conditions (Lloyd, 2013b). 
Due to the deviation from the OECD Guideline 487 (OECD, 2010) the study is considered of limited 
validity.  
Allyl alpha-ionone [FL-no: 07.061] 
Allyl alpha-ionone was evaluated in an in vitro micronucleus assay in human peripheral blood 
lymphocytes (Table 7). Information about the method used to induce lymphocytes cell division and 
the duration of the induction before the treatment was not provided. Cells were treated for 24 hours 
with 14 concentrations in a range from 5 to 50 µg/ml of allyl alpha-ionone in absence of S9-mix. In 
presence of S9-mix cells were exposed for 3 hours followed by 21 hours recovery with 15 
concentrations in a range from 25 to 200 µg/ml. Based on the toxicity induced by alpha-ionone three 
concentrations were selected for micronuclei assessment. In absence of S9-mix (24 hours treatment), 
cells were treated with 25, 33, 36 and 38 µg/ml, while in presence of S9-mix (3 hours treatment) the 
concentrations selected were 110, 140, 150 and 160 µg/ml. The highest concentrations induced 54 % 
and 63 % reduction of RI in absence and presence of S9-mix, respectively. Micronuclei assessment 
was performed in a single experiment with duplicates and a total of 2000 binucleate cells per replicate 
were scored in the experiment performed in absence of S9-mix, while 1000 binucleated cells were 
scored in presence of S9-mix. No assay with 3-hour treatment + 21-hour recovery in absence of S9-
mix was performed as recommended by OECD Guideline 487 (OECD, 2010). 
Treatment of cells with allyl alpha-ionone for 3 hours with a 21 hours recovery period in the presence 
of S9-mix or for 24 hours with no recovery period in the absence of S9-mix showed no increase in the 
frequency of MNBN cells at any concentration when compared to both concurrent and historical 
controls. It was concluded that allyl alpha ionone did not induce micronuclei at concentration up to the 
limit of toxicity when assayed in cultured human peripheral lymphocytes in the described exposure 
conditions (Lloyd, 2013a).  
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Due to the deviation from the OECD Guideline 487 (OECD, 2010) the study is considered of limited 
validity.  
alpha-Damascone [FL-no: 07.134] 
Three in vitro micronucleus experiments have been performed in human peripheral blood lymphocytes 
to determine whether alpha-damascone is able to induce chromosomal damage or aneuploidy in the 
presence and absence of rat S9 fraction as an in vitro metabolising system (Table 7).  
In all three experiments cells were stimulated for 48 hours with phytohaemaglutinin to produce 
exponentially growing cells.  
A first experiment (Lloyd, 2012) was performed using standard conditions. Human peripheral blood 
lymphocytes were treated with alpha-damascone (purity 98.3 %) for 3 hours (followed by 21 hours 
recovery) with 9, 16, 18 or 22 μg/ml and 12, 18, 20, 21 or 22 μg/ml of alpha-damascone in the absence 
and presence of S9-mix, respectively. The levels of cytotoxicity (reduction in replication index) at the 
top concentrations were 55 % and 56 %, respectively. In a parallel assay, cells were treated for 24 
hours with 5, 7, 9 and 10 μg/ml of alpha-damascone in the absence of S9-mix with no recovery period. 
The top concentration induced 57 % cytotoxicity. Cytotoxicity was observed at the top concentrations 
in all parts of the study. There were two replicate cultures per treatment and 1000 binucleate cells per 
replicate were scored for micronuclei. The study design complies with OECD Guideline 487 (OECD, 
2010) and follows GLP principles. Treatment of cells with alpha-damascone for 3 hours with a 21 
hour recovery period in the absence of S9-mix or for 24 hours with no recovery period in the absence 
of S9-mix showed no increase in the frequency of MNBN cells at any concentration when compared 
to both concurrent and historical controls. Treatment of cells with alpha-damascone for 3 + 21 hours in 
the presence of S9-mix resulted in frequencies of MNBN cells that were significantly higher (p < 
0.001) when compared to concurrent controls at the two highest test concentrations with 1.40 and 1.70 
% MNBN at 21 and 22 µg/ml compared to 0.25 % MNBN cells in the concurrent control. It is noted 
that although the frequencies of MNBN cells exceed the 95
th
 percentile of the historical controls (0.1 - 
1.2 % MNBN) they are still within the normal range when considering the total range (0 - 2.0 % 
MNBN). An additional reading on 1000 BN cells scored per replicate confirmed the statistically 
significant increase with 1.03 and 1.0 % MNBN cells at 21 and 22 µg/ml; however, no additional 
reading was performed in the controls. It was concluded that alpha-damascone showed weak induction 
of micronuclei when assayed in cultured human peripheral lymphocytes for 3+21 hours in the 
presence of S9-mix, while in absence of S9-mix no induction of micronuclei were observed when 
tested up to toxic concentrations for 3 + 21 hours and 24 + 0 hours (Lloyd, 2012). 
Since this study (Lloyd, 2012) showed a variable toxicity profile in the treatment for 3 hours with a 21 
hours recovery period in the presence of S9-mix, a follow-up in vitro micronucleus assay was 
performed (Whitwell, 2012). alpha-Damascone was tested on human lymphocyte cultures using 
different methods of addition/mixing the test substance to the treatment medium, in order to assess and 
compare the cytotoxicity. A high variability in cytotoxicity was observed and it was concluded that 
where alpha-damascone is prepared for 100 % medium replacement and treated in a large volume 
vessel with vigorous mixing, a smoother and steeper toxicity curve is obtained as compared to using a 
standard method of addition to the test system. The micronucleus assay was performed using 3 
different methods of adding/mixing alpha-damascone to the treatment medium: standard treatment in 
larger volume vessel (experiment 1), standard treatment in standard vessel (experiment 2) and 100 % 
medium replacement in a larger volume vessel (experiment 3). The following concentrations were 
tested: 7.5 to 14 μg/ml (experiment 1 and 3), 14 to 20 μg/ml (experiment 2). Data indicated a positive 
induction of MNBN cells for at least one concentration for each experiment with a concentration-
dependent effect.  
Repetition of the experiments under slightly different conditions (with respect to the volume of vessel, 
mixing conditions and medium replacement) resulted in similar induction of micronuclei. The author 
of the repeated study concluded that alpha-damascone did not induce consistent and biologically 
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relevant increases in the frequency of micronuclei in cultured human peripheral blood lymphocytes 
when tested for 3+21 hours in the presence of S9-mix and for 24+0 hours in the absence of S9-mix 
(Lloyd, 2013c). 
The Panel noted that statistically significant increases of MNBN cells were observed at concentrations 
that are above the limits of cytotoxicity recommended by the guideline and that the increases were 
higher than the 95
th
 percentile of the historical control, but that the effects were observed only at the 
high concentrations at a cytotoxicity level higher than 55 %. Under these conditions, the Panel 
concluded that alpha-damascone presents, in this study, an equivocal effect in the in vitro 
micronucleus test. 
The results of  in vitro micronucleus studies are summarised in Table 7. 
4.3. In vivo data 
4.3.1. Bone Marrow Micronucleus Assay 
alpha-Ionone [FL-no: 07.007] 
alpha-Ionone was tested in a mouse bone marrow micronucleus assay (Krsmanovic and Huston, 
2006). An initial extensive range-finding test established a maximum tolerated dose (MTD) of 1200 
mg/kg. Animals were dosed by a single intraperitoneal injection, either with vehicle or with alpha-
ionone at 300, 600 or 1200 mg/kg. Groups of 5 male and 5 female mice from all treatment levels were 
sacrificed 24 hours after dosing, and additional 5 mice of each sex from top dose and vehicle control 
groups were also sacrificed at 48 hours after dosing (Table 8).  
2000 Polychromatic (PCE) and normochromatic (NCE) erythrocytes per animal were scored for 
micronuclei. Reductions of 7 - 18 % in PCE were observed in treated males and females at 24 hours 
after dosing; a reduction of 21 % in PCE was observed in males at the top dose at 48 hours after 
dosing, indicating bone marrow toxicity. Systemic availability was confirmed by additional clinical 
signs in treated animals. There were no statistically or biologically significant increases in 
micronucleus frequency in treated animals. The study is compliant with OECD Guideline 474 (OECD, 
1997b) and is sufficiently robust to contribute to the evaluation of clastogenic or aneugenic potential 
of alpha-ionone. 
CONCLUSION 
In the first evaluation of the available data on α,β-unsaturated alicyclic ketones and precursors in 
FGE.210 (subgroup 2.4 of FGE.19), it was concluded that additional data should be provided for the 
proper consideration of the genotoxic potential of these substances (EFSA, 2009). 
New in vitro data have been submitted for five substances of FGE.19 subgroup 2.4 (FGE.210), four 
representatives (alpha-ionone [FL-no: 07.007], alpha-damascone [FL-no: 07.134], allyl alpha-ionone 
[FL-no: 07.061], beta-ionone epoxide [FL-no: 07.170]), as requested, and one other substance, delta-
damascone [FL-no: 07.130]. Furthermore, new in vivo data have been submitted for the representative 
alpha-ionone [FL- no: 07.007].   
alpha-Ionone [FL-no: 07.007] did not induce gene mutation in S. typhimurium nor structural or 
numerical chromosomal aberrations when tested with human peripheral lymphocytes. The latter study 
is of limited validity due to deviation to the OECD Guideline 487 (OECD, 2010) and it is not a GLP 
study. However, alpha-ionone was tested in an in vivo mouse bone marrow micronucleus assay in 
which no statistically significant increase in the frequency of micronucleated cells was observed. 
There was an indication for bone marrow exposure, thus, the result is considered reliable. 
The new data submitted for beta-ionone epoxide [FL-no: 07.170] included two in vitro studies in 
bacteria and mammalian cells. beta-Ionone epoxide did not induce any significant increase in bacterial 
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mutation when evaluated in five different S. typhimurium strains and an E. coli strain, either in the 
presence or absence of S9 metabolic activation in two independent studies. beta-Ionone epoxide also 
did not increase mutation frequencies when tested in a tk mutation assay using mouse lymphoma cells 
either in the presence or absence of S9 metabolic activation. No in vitro assay for chromosomal 
aberration is available, but the mouse lymphoma assay is a test that is able to detect the chemical 
potential to induce structural chromosomal aberrations. The lack of an in vitro micronucleus assay is 
not consistent with the current EFSA guideline (EFSA Scientific Committee, 2011), it is however 
consistent with the genotoxicity test strategy for substances belonging to subgroups of FGE.19 (EFSA, 
2008b) applicable at the time when the scientific opinion on FGE.210 was adopted (EFSA, 2009). The 
Panel concluded that the data submitted for beta-ionone epoxide are sufficient in the light of data 
available for structurally related substances. 
Therefore, the Panel concluded that based on the current data on the representative substances alpha-
ionone [FL-no: 07.007] and beta-ionone epoxide [FL-no: 07.170], the concern with respect to 
genotoxicity could be ruled out as well as for the six other substances [FL-no: 02.105, 07.009, 07.011, 
07.036, 07.088 and 07.091] structurally related to ionone. Accordingly these eight substances can be 
evaluated through the procedure.  
Allyl alpha-ionone [FL-no: 07.061] is, due to a terminal double bond, not considered sufficiently 
structurally related to the other ionones. For allyl alpha-ionone [FL-no: 07.061], two in vitro studies 
were submitted, a bacterial reverse mutation assay and a micronucleus assay in human peripheral 
blood lymphocytes. The bacterial mutation assay has been performed only in TA102 strain of S. 
typhimurium, in the presence and absence of S9 metabolic activation, where no indication of mutation 
has been observed. A study was previously performed in the other four strains of S. typhimurium and 
there was no indication of mutation after treatment with allyl alpha-ionone. Allyl alpha-ionone did not 
induce chromosomal damage or aneuploidy when tested with human peripheral blood lymphocytes in 
the absence and presence of S9 metabolic activation. This study is of limited validity due to deviations 
from the OECD Guideline 487 (OECD, 2010). In fact, the treatment of cells for 3 hours (with 21 hours 
recovery) in the absence of S9-mix was not performed. Therefore an in vitro micronucleus assay with 
treatment for 3 hours (with 21 hours recovery) in the absence of S9-mix should be performed.  
alpha-Damascone [FL-no: 07.134] did not induce any significant increase in bacterial mutation 
frequency when evaluated in four histidine-requiring strains (TA98, TA100, TA1535 and TA1537) of 
S. typhimurium and E. coli WP2uvrA in presence and absence of metabolic activation. 
alpha-Damascone did induce statistically significant chromosomal damage or aneuploidy when tested 
in the in vitro micronucleus test with human peripheral lymphocytes in the absence and presence of S9 
metabolic activation. However, the results with alpha-damascone were difficult to interpret due to the 
difficulty in assessing the cytotoxicity of the test substance to the peripheral blood human 
lymphocytes. The Panel concluded that the study result was equivocal.  
The current data available for alpha-damascone [FL-no: 07.134] cannot be used to exclude a genotoxic 
concern and accordingly the Panel requests additional data for this substance in order to conclude on 
the genotoxicity of this substance and the four structurally related substances [FL-no: 07.130, 07.225, 
07.226 and 07.231].  
Overall, the Panel concluded that the concern for genotox potential is ruled out for eight of the 
substances [FL-no: 02.105, 07.007, 07.009, 07.011, 07.036, 07.088, 07.091 and 07.170]. These eight 
substances can accordingly be evaluated using the Procedure. For allyl alpha-ionone [FL-no: 07.061] 
and for alpha-damascone [FL-no: 07.134] and the four structurally related substances [FL-no: 07.130, 
07.225, 07.226 and 07.231], the new submitted data could not rule out the Panel concern with respect 
to genotoxicity and additional data are requested. 
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SUMMARY OF SPECIFICATION FOR SUBSTANCES IN FGE.210REV1 (JECFA, 1998; JECFA, 2005) 
Table 2:  Summary of Specification for the Substances in the Flavouring Group Evaluation 210Rev1 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
02.105 
391 
4-(2,6,6-Trimethyl-2-
cyclohexenyl)but-3-en-2-ol 
OH
 
3624 
 
25312-34-9 
Liquid 
C13H22O 
194.32 
 
 
127 (20 hPa) 
 
IR 
99 % 
1.488-1.492 
0.917-0.924 
07.007 
388 
alpha-Ionone 
O
 
2594 
141 
127-41-3 
Liquid 
C13H20O 
192.30 
Insoluble 
1 ml in 3 ml 70% 
alcohol 
237 
 
IR 
85 % 
1.497-1.502 
0.927-0.933 
07.009 
398 
Methyl-alpha-ionone 
O
 
2711 
143 
7779-30-8 
Liquid 
C14H22O 
206.33 
 
 
238 
 
IR 
90 % 
1.498-1.503 
0.921-0.930 
07.011 
403 
4-(2,5,6,6-Tetramethyl-2-
cyclohexenyl)-3-buten-2-
one 
O
 
2597 
145 
79-69-6 
Liquid 
C14H22O 
206.33 
 
1 ml in 4 ml 70% 
alcohol 
110-112 (4 hPa) 
 
IR 
98 % 
1.497-1.503 
0.932-0.939 
07.036 
404 
alpha-Isomethyl ionone 
O
 
2714 
169 
127-51-5 
Liquid 
C14H22O 
206.33 
 
 
238 
 
IR 
85 % 
1.498-1.503 
0.925-0.934 
07.061 
401 
Allyl alpha-ionone 
O
 
2033 
2040 
79-78-7 
Liquid 
C16H24O 
232.37 
Insoluble 
1 ml in 1 ml 90% 
alcohol 
265 
 
IR 
88 % 
1.502-1.507 
0.926-0.935 
07.088 
400 
Methyl-delta-ionone 
O
 
2713 
11852 
7784-98-7 
Liquid 
C14H22O 
206.33 
Insoluble 
 
232 
 
IR 
95 % 
1.493-1.499 
0.931-0.938 
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Table 2:  Summary of Specification for the Substances in the Flavouring Group Evaluation 210Rev1 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
07.091 
390 
gamma-Ionone 
O
 
3175 
 
79-76-5 
Liquid 
C13H20O 
192.30 
 
 
125 (13 hPa) 
 
NMR MS 
95 % 
1.496-1.502 (25°) 
0.932-0.935 (20°) 
07.130 
386 
delta-Damascone 
O
 
3622 
 
57378-68-4 
Liquid 
C13H20O 
192.30 
 
1 ml in 10 ml 95% 
alcohol 
82 (3 hPa) 
 
IR 
96.5 % 
1.485-1.502 
0.920 -0.940 
07.134 
385 
alpha-Damascone 
O
 
3659 
11053 
43052-87-5 
Liquid 
C13H20O 
192.30 
 
 
90-100 
 
IR 
98 % 
1.492-1.499 
0.928-0.938 
07.170 
1571 
beta-Ionone epoxide    
O
O
 
4144 
11202 
23267-57-4 
Solid 
C13H20O2 
208.30 
Insoluble 
Soluble 
 
48 
NMR MS 
95 % 
n.a. 
n.a. 
07.225 
 
cis-1-(2,6,6-Trimethyl-2-
cyclohexen-1-yl)but-2-en-1-
one 
O  
3659 
11053 
23726-94-5 
Liquid 
C13H20O 
192.3 
Insoluble 
Soluble 
 
 
MS 
92 % 
1.492-1.499 
0.928-0.938 
07.226 
 
tr-1-(2,6,6-Trimethyl-2-
cyclohexen-1-yl)but-2-en-1-
one 
O
 
 
 
24720-09-0 
Liquid 
C13H20O 
192.30 
 
Freely soluble 
54 (0.1 hPa) 
 
 
95 % 
1.493-1.499 
0.937-0.943 
07.231 
 
alpha-Damascenone    
O
 
 
 
35044-63-4 
Liquid 
C13H18O 
190.28 
Practically insoluble 
or insoluble 
Freely soluble 
51 (0.1 hPa) 
 
MS 
95 % 
1.502-1.508 
1.015-1.021 
1) Solubility in water, if not otherwise stated. 2) Solubility in 95 % ethanol, if not otherwise stated. 3) At 1013.25 hPa, if not otherwise stated. 4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (JECFA, 1999; JECFA, 2006) 
Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/
day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
02.105 
391 
4-(2,6,6-Trimethyl-2-
cyclohexenyl)but-3-en-2-ol 
OH
 
0.61 
0.06 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No further EFSA 
considerations needed. 
07.007 
388 
alpha-Ionone 
O
 
270 
150 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No further EFSA 
considerations needed. 
07.009 
398 
Methyl-alpha-ionone 
O
 
86 
7 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No further EFSA 
considerations needed. 
07.011 
403 
4-(2,5,6,6-Tetramethyl-2-
cyclohexenyl)-3-buten-2-one 
O
 
7.7 
3 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No further EFSA 
considerations needed. 
07.036 
404 
alpha-Isomethyl ionone 
O
 
4.7 
1 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No further EFSA 
considerations needed. 
07.061 
401 
Allyl alpha-ionone 
O
 
30 
25 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could not be 
ruled out. Additional genotoxicity 
data required. 
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Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/
day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
07.088 
400 
Methyl-delta-ionone 
O
 
0.37 
1 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No further EFSA 
considerations needed. 
07.091 
390 
gamma-Ionone 
O
 
0.012 
15 
Class I 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Evaluated by JECFA 
before 2000. No further EFSA 
considerations needed. 
07.130 
386 
delta-Damascone 
O
 
0.049 
0.6 
Class I 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could not be 
ruled out. Additional genotoxicity 
data required.  
07.134 
385 
alpha-Damascone 
O
 
6.9 
0.4 
Class I 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) Evaluated in FGE.210Rev1, 
genotoxicity concern could not be 
ruled out. Additional genotoxicity 
data required.  
07.231 
 
alpha-Damascenone 
O
 
0.57 
 
Class I 
No evaluation 
Not evaluated by 
JECFA 
Evaluated in FGE.210Rev1, 
genotoxicity concern could not be 
ruled out.  Additional 
genotoxicity data required. 
07.170 
1571 
beta-Ionone epoxide 
O
O
 
0.073 
0.1 
Class III 
No evaluation 
Not evaluated by 
JECFA 
Evaluated in FGE.210Rev1, 
genotoxicity concern could be 
ruled out. Can be evaluated using 
the Procedure. 
07.225 
 
cis-1-(2,6,6-Trimethyl-2-
cyclohexen-1-yl)but-2-en-1-
one 
O  
24 
 
 
No evaluation 
Not evaluated by 
JECFA 
Evaluated in FGE.210Rev1, 
genotoxicity concern could not be 
ruled out.Additional genotoxicity 
data required. 
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Table 3:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
( g/capita/
day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
07.226 
 
tr-1-(2,6,6-Trimethyl-2-
cyclohexen-1-yl)but-2-en-1-
one 
O
 
0.011 
 
 
No evaluation 
Not evaluated by 
JECFA 
Evaluated in FGE.210Rev1, 
genotoxicity concern could not be 
ruled out. Additional genotoxicity 
data required. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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QSAR PREDICTIONS ON MUTAGENICITY IN FIVE MODELS FOR 10 KETONES FROM SUBGROUP 2.4 
Table 4:  QSAR Predictions on Mutagenicity in Five Models for 12 Ketones from Subgroup 2.4 
FL-no 
JECFA-no 
EU Register name Structural formula ISS Local Model 
Ames Test TA100 
 
MultiCASE 
Ames test 
 
MultiCASE 
Mouse lymphoma 
test 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
07.007 
388 
alpha-Ionone 
O
 
NEG NEG NEG NEG EQU 
07.009 
398 
Methyl-alpha-ionone 
O
 
NEG NEG OD NEG EQU 
07.011 
403 
4-(2,5,6,6-Tetramethyl-2-cyclohexenyl)-3-
buten-2-one O
 
NEG NEG OD NEG EQU 
07.036 
404 
alpha-Isomethyl ionone 
O
 
NEG NEG NEG NEG NEG 
07.061 
401 
Allyl alpha-ionone 
O  
NEG NEG NEG NEG EQU 
07.088 
400 
Methyl-delta-ionone 
O
 
NEG NEG OD OD EQU 
07.091 
390 
gamma-Ionone 
O
 
NEG NEG NEG NEG EQU 
07.130 
386 
delta-Damascone 
O
 
NEG NEG NEG NEG EQU 
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Table 4:  QSAR Predictions on Mutagenicity in Five Models for 12 Ketones from Subgroup 2.4 
FL-no 
JECFA-no 
EU Register name Structural formula ISS Local Model 
Ames Test TA100 
 
MultiCASE 
Ames test 
 
MultiCASE 
Mouse lymphoma 
test 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
07.134 
385 
alpha-Damascone 
O
 
NEG NEG OD NEG OD 
07.231 
 
alpha-Damascenone  
O
 
NEG NEG OD OD OD 
07.170 beta-Ionone epoxide    
O
O
 
NYA NEG OD OD OD 
07.226 tr-1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)but-
2-en-1-one 
O
 
NYA NEG NEG NEG OD 
Column 3: Structure group 2.4: , -unsaturated ketones. 
Column 4: Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD*: out of domain). 
Column 5: MultiCase Ames test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 6: MultiCase Mouse Lymphona test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 7: MultiCase Chromosomal aberration in CHO (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
Column 8: MultiCase Chromosomal aberration in CHL (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
*  OD, out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, 
biological etc. 
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.210 
Table 5:  Genotoxicity Data (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Reported 
Result  
Reference  Comments c 
alpha-Ionone [07.007] Chromosomal 
aberration  
Chinese hamster B241 cell line 25 nmol/L Positivea  (Kasamaki et 
al., 1982) 
Limited validity  (limited documentation; 
results for only one test concentration 
reported; long incubation period of 24 
hours; unusual cell line) 
Reverse mutation  S. typhimurium TA98, TA100 0.01 - 50 µg/plate Negativea (Kasamaki et 
al., 1982) 
Limited validity (insufficiently reported. 
Only two strains). 
Rec assay  B. subtilis H17 & M45    19 mg/disc Negativeb (Oda et al., 
1978) 
Insufficient validity.  This bacterial DNA-
repair test system is of low predictive 
value for genotoxicity 
Methyl-alpha-ionone [07.009] Reverse  mutation  S. typhimurium TA1535, 
TA1537, TA1538, TA98, 
TA100 
5 concentrations up to 
cytotoxicity or max 3600 
µg/plate 
Negativea (Wild et al., 
1983) 
Limited validity (no TA102 or E. Coli) 
Methyl-delta-ionone [07.088] Reverse  mutation  S. typhimurium TA1535, 
TA1537, TA1538, TA98, 
TA100 
5 concentrations up to 
cytotoxicity or max 3600 
µg/plate 
Negativea (Wild et al., 
1983) 
Limited validity (no TA102 or E. Coli) 
a: With and without metabolic activation 
b: Activation status unknown 
c: Validity of genotoxicity studies: 
 Valid 
 Limited validity (e.g. if certain aspects are not in accordance with OECD Guidelines or current standards and / or limited documentation) 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system) 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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GENOTOXICITY DATA (IN VIVO) CONSIDERED BY THE PANEL IN FGE.210 
Table 6:  Genotoxicity Data (in vivo) 
Chemical Name 
[FL-no]  
Test System Test Object  Route Dose Reported 
Result  
Reference  Comments a 
Methyl alpha-ionone 
[07.009] 
Micronucleus 
formation  
NMRI mice, male and 
female, bone marrow 
I.P.  825 - 2063 
mg/kg bw 
Negative  (Wild et al., 1983) Limited validity (only analysis at one time 
point; no PCE/NCE ratio reported) 
Sex-linked recssive 
lethals  
Drosophila 
melanogaster   
Feed   20 mM Negative  Limited validity (limited reporting, test system 
considered of limited relevance) 
a: Validity of genotoxicity studies: 
 Valid. 
 Limited validity (e.g. if certain aspects are not in accordance with OECD Guidelines or current standards and / or limited documentation). 
 Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system). 
 Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided). 
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.210REV1 
Table 7:  Additional Genotoxicity Data (in vitro) 
Chemical Name 
FL-no 
Test System 
in vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
alpha-Ionone 
[07.007] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 and TA102 
0.3 - 5000 μg/plate [1,3] 
0.3 - 5000 μg/plate [2,3] 
Negative 
Negative  
(Bowen, 2011) 
 
Toxicity was observed at 1000 and/or 5000 
μg/plate across all strains in the absence and 
presence of S9-mix; no clear evidence of 
toxicity in TA100 in the presence of S9-mix. 
No statistically significant increase in 
revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
S. typhimurium  
TA98  
 
TA100 
 
156.3 - 5000 μg/plate [2,4] 
 
156.3 - 5000 μg/plate [1,3] 
or [2,4] 
 
 
Negative 
 
Negative 
Evidence of toxicity was observed at the 
highest three or four concentrations across all 
strains in the absence and presence of S9-mix. 
No statistically significant increase in 
revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
S. typhimurium  
TA98 
 
TA1535, TA1537 and 
TA102 
 
 
78.1 – 2500 μg/plate [1,3]   
 
78.1 – 2500 μg/plate [1,3] 
or [2,4] 
 
 
Negative  
 
Negative  
Evidence of toxicity was observed at the 
highest three or four concentrations across all 
strains in the absence or presence of S9-mix. 
No statistically significant increase in 
revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
 S. typhimurium 
TA1535  
 
TA102 
 
 
TA1537 
39.1 - 2500 μg/plate [1,3] or 
[2,4] 
 
19.5 - 1250 μg/plate [1,3] or 
[2,4] 
 
19.5 - 1250 μg/plate [2,4] 
 
Negative  Evidence of toxicity was observed at the 
highest three or four concentrations across all 
strains in the absence or presence of S9-mix. 
No statistically significant increase in 
revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
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Table 7:  Additional Genotoxicity Data (in vitro) 
Chemical Name 
FL-no 
Test System 
in vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
Micronucleus 
Induction 
Human peripheral 
blood lymphocytes 
160 - 180 μg/ml [2,8] 
40 - 65 μg/ml [1,9] 
Negative 
Negative  
(Lloyd, 2013b) The MNBN cell frequencies in all treated 
cultures fell within the normal range. The 
study does not comply with OECD Guideline 
487 therefore it has limited validity 
Allyl alpha-ionone 
[07.061] 
Reverse 
Mutation 
S. typhimurium TA102 1.6 - 5000 μg/plate [1,3] or 
 [2,3] 
Negative  (Ballantyne, 
2011) 
No evidence of toxicity was observed at any 
concentration. No statistically significant 
increase in revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
 51.2 - 5000 μg/plate [1,3] or 
 [2,4] 
Negative  No evidence of toxicity was observed at any 
concentration. No statistically significant 
increase in revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
Reverse 
Mutation 
S. typhimurium 
TA1535, TA100, 
TA1537, TA1538, 
TA98 
Five concentrations up to 
cytotoxicity or max 3600 
μg/plate [1,3] 
Negative (Wild et al., 1983) Limited validity (no TA102 or E. Coli). 
Micronucleus 
Induction 
Human peripheral 
blood lymphocytes 
110 - 160 μg/ml [2,8] 
25 - 38 μg/ml [1,9] 
Negative  
Negative  
(Lloyd, 2013a) The MNBN cell frequencies in all treated 
cultures fell within the normal range. The 
study does not comply with OECD Guideline 
487, therefore it has limited validity. 
delta-Damascone 
[07.130] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535 and 
TA1537 
4.9 - 5000 μg/plate [4,5] 
 
Negative 
 
(Shinya, 2006) 
 
Evidence of toxicity was observed at the top 
three or four concentrations tested. No 
statistically significant increase in revertant 
numbers was seen at any concentration, either 
in the presence or absence of S9-mix. 
  S. typhimurium TA98, 
TA100, TA1535 and 
TA1537 
2.4 - 78.1 μg plate [1,4] 
9.8 - 313 μg/plate [2,4] 
Negative 
 
 Evidence of toxicity was observed at the top 
concentration in all strains in the absence of 
S9-mix and at 156 μg/plate or above in the 
presence of S9-mix. The study complies with 
current recommendations for upper 
concentration limit inclusion. The study 
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Table 7:  Additional Genotoxicity Data (in vitro) 
Chemical Name 
FL-no 
Test System 
in vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
included 3 replicate plates per concentration, 
and was GLP compliant. 
  E. coli WP2 uvrA 4.9 – 5000 μg/plate [5,4] Negative  Evidence of toxicity was observed at the top 
three or four concentrations tested. No 
statistically significant increase in revertant 
numbers was seen at any concentration, either 
in the presence or absence of S9-mix. 
  E. coli WP2 uvrA 2.4 - 78.1 μg/plate [1,4] 
9.8 – 313 μg/plate [2,4] 
Negative 
 
 Evidence of toxicity was observed at the 
highest concentration in the presence of S9-
mix. The study complies with current 
recommendations for upper concentration 
limit inclusion. The study included 3 replicate 
plates per concentration, and was GLP 
compliant. 
alpha-Damascone 
[07.134] 
Reverse 
mutation 
S. typhimurium TA98 
and TA100 
10 – 5000 µg/plate [5,3] 
 
Negative  
 
(Haddouk, 2001) 
 
In TA98, slight to marked toxicity was 
observed at concentrations > 100 μg/plate or 
500 μg/plate with and without S9-mix, 
respectively. In TA100, toxicity was observed 
at concentrations > 500 μg/plate with and 
without S9-mix.  
S. typhimurium 
TA1537, TA98  
7.8 – 125 μg/plate [5,3] 
15.6 – 250 μg/plate [2,4] 
Negative  
Negative  
 Slight toxicity was observed in all strains. No 
statistically significant increase in revertant 
numbers was seen at any concentration, either 
in the presence or absence of S9-mix. 
S. typhimurium 
TA100 and TA1535 
31.2 – 500 μg/plate [5,3] 
31.2 – 500 μg/plate [2,4] 
Negative  
Negative  
 Slight toxicity was observed in all strains. No 
statistically significant increase in revertant 
numbers was seen at any concentration, either 
in the presence or absence of S9-mix. 
S. typhimurium 
TA1535, TA1537, 
TA98 and TA100 
15.6 – 250 μg/plate [1,3] 
 
Negative 
 
 Slight toxicity was observed in all strains. No 
statistically significant increase in revertant 
numbers was seen at any concentration  
E. coli WP2uvrA 10 - 5000μg/plate [5,3] 
 
Negative   Slight toxicity was observed at 2500 μg/plate 
and above without S9-mix. 
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Table 7:  Additional Genotoxicity Data (in vitro) 
Chemical Name 
FL-no 
Test System 
in vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
E. coli WP2 uvrA 312.5 – 5000 μg/plate [5,3] 
312.5 – 5000 μg/plate [1,3] 
or  [2,4] 
Negative  
Negative  
 Slight toxicity was observed only at the 
highest concentration tested without S9-mix. 
No statistically significant increase in 
revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
Micronucleus 
Induction 
Human peripheral 
blood lymphocytes 
9 - 22 μg/ml [1,8] 
12 - 22 μg/ml [2,8] 
5 - 10 μg/ml [1,9] 
Negative  
Weakly positive  
Negative  
(Lloyd, 2012) Weakly positive result was obtained only in 
the 3+21 hours treatment in the presence of 
S9-mix. Study design complies with OECD 
Guideline 487. 
7.5 - 14 μg/ml [2,8,10] 
14 - 20 μg/ml [2,8,9] 
7.5 - 14 μg/ml [2,8,10] 
Positive (Whitwell, 2012) Follow-up study to explore different methods 
of mixing and sample preparation to overcome 
the challenges in inconsistent cytotoxicity that 
results in difficulties in choosing 
concentrations for scoring of micronucleated 
binucleate cells. Experiment conducted only 
for 3+21 hours in the presence of S9-mix. 
10 - 18 μg/ml [2,8] 
7 - 14 μg/ml [1,9] 
Positive at high toxic 
concentrations only  
 
(Lloyd, 2013c) 
 
Positive results were obtained only at high 
toxic concentrations in both test conditions.  
Study is robust and complies with GLP. 
beta-Ionone 
epoxide [07.170] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, and 
TA1537 
5 - 500 μg/plate [5,3] Negative  (Jones and 
Wilson, 1988) 
No statistically significant increase in 
revertant numbers was seen at any 
concentration, either in the presence or 
absence of S9-mix. 
S. typhimurium TA97a, 
TA98, TA100, TA1535 
501, 1582 and 5000 
μg/plate [1,3] 
158, 501 and 1582 μg/plate 
[2,3] 
Negative  
 
Negative  
 
(Kringstad, 2005) Evidence of toxicity was observed at the 
highest concentration in strain TA97a in the 
absence of S9-mix and in TA100 in the 
absence and presence of S9-mix. The study 
therefore complies with current 
recommendations for upper concentration 
limit inclusion. The study included 3 replicate 
plates per concentration, and was GLP 
compliant. 
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Table 7:  Additional Genotoxicity Data (in vitro) 
Chemical Name 
FL-no 
Test System 
in vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
 E. coli WP2uvrA 501, 1582 and 5000 
μg/plate [1,3] 
158, 501 and 1582 μg/plate 
[2,3] 
Negative 
 
Negative  
 
  
tk Mutation 
Induction 
Mouse Lymphoma 
L5178Y T/K +/- 3.7.2c 
cells 
200 - 900 μg/ml [5,6] 
4.1 - 520 μg/ml [1,7] 
Negative 
Negative 
(Flanders, 2006) A preliminary range-finder assay was 
conducted to establish maximum 
concentrations. Top concentrations in each 
arm of the study induced 77, 85, and 80% 
reductions in relative total growth. The study 
therefore complies with current 
recommendations. 
[1] Without S9 metabolic activation. 
[2] With S9 metabolic activation. 
[3] Plate incorporation method. 
[4] Pre-incubation with S9 method. 
[5] With and without S9 metabolic activation. 
[6] 4-hour treatment. 
[7] 24-hour treatment. 
[8] 3-hour treatment with 21-hour recovery. 
[9] 24-hour treatment with 0-hour recovery. 
[10] Standard treatment in larger-than-typical vessel 
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GENOTOXICITY DATA (IN VIVO) CONSIDERED BY THE PANEL IN FGE.210REV1 
Table 8:  Additional Genotoxicity Data (in vivo) 
Chemical Name 
[FL-no]  
Test System Test Object  Route Dose Reported 
Result  
Reference  Comments a 
alpha-Ionone 
[07.007] 
Micronucleus 
formation  
Male and female 
mice 
Intraperiton
eal 
300, 600 and 1200 
mg/kg bw/day 
Negative  (Krsmanovic and 
Huston, 2006) 
Study complies with OECD Guideline 474. 
Evidence of bone marrow toxicity as evidenced 
by reductions in polychromatic erythrocytes 
observed at 24 hours after dosing and in a 
satellite group at the top dose 48 hours after 
dosing. 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body Weight 
CA  Chromosomal Aberrations 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids  
CHO  Chinese hamster ovary (cells) 
CHL  Chinese Hamster Lung (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
ID   Identity 
IOFI  International Organization of the Flavor Industry 
IR   Infrared spectroscopy 
JECFA  Joint FAO/WHO Expert Committee on Food Additives 
MNBN  Micronucleated binucleate cells 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
MTD   Maximum Tolerated Dose  
NCE   Normochromatic Erythrocytes 
No  Number 
NOAEL No Observed Adverse Effect Level 
PCE   Polychromatic Erythrocytes 
OECD  Organisation for Economic Co-operation and Development 
QSAR  Quantitative Structure-Activity Relationship 
WHO  World Health Organisation 
